Court Denies ANI's Post-Trial Motions in CG Oncology Dispute; Appeal Planned
ANIP sits 31% above its 52-week low of $62.605.
Summary
A Delaware court denied ANI Pharmaceuticals' post-trial motions for a new trial and judgment as a matter of law in its dispute with CG Oncology. ANI intends to appeal to the Delaware Supreme Court, seeking a 5% running royalty on future worldwide sales of cretostimogene grenadenorepvec. The ruling is a setback in ANI's effort to recover value from assets sold under a 2010 agreement. The appeal process introduces uncertainty and potential legal costs, though the ultimate financial impact depends on the drug's commercial success and the appeal's outcome.
At the time of this announcement, ANIP was trading at $81.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $62.61 to $99.50. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.